CLYM Latest Press Releases

-- November 5, 2026 --

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- November 4, 2026 --

Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition Globe Newswire 9:00 AM

-- November 2, 2026 --

Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference Globe Newswire 7:00 AM

-- October 24, 2026 --

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 Globe Newswire 7:30 PM

-- October 23, 2026 --

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 Globe Newswire 4:01 PM

-- October 2, 2026 --

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug Globe Newswire 9:30 AM

-- September 3, 2026 --

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy Globe Newswire 7:00 AM

-- September 2, 2026 --

Climb Bio to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 6, 2026 --

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- June 11, 2026 --

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes